| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 0.37 | 99.8% |
| Total Income | 0.37 | 99.8% |
| Expenditure | 26.24 | 55.7% |
| PBT | -23.71 | 115.0% |
| Net Profit | -23.71 | 116.0% |
| OPM | — | |
| NPM | — | |
| EPS | -1.21 | 133.1% |
Keros Therapeutics Reports Q1 2026 Financial Results
14 May 2026 · 14 May, 5:37 pm
Summary
Keros Therapeutics reported its financial results for the quarter ended March 31, 2026. The company reported a net loss of $23.7 million, a decrease compared to the net income of $148.5 million in the first quarter of 2025. This decrease was primarily due to revenue recognized in 2025 from a license agreement with Takeda and reduced research and development efforts. The company's cash and cash equivalents were $281.5 million as of March 31, 2026, and are expected to fund operations into the first half of 2028.
Key Highlights
- 1
Keros Therapeutics reported a net loss of $23.7 million in the first quarter of 2026, compared to a net income of $148.5 million in the first quarter of 2025.
- 2
Research and development expenses decreased by $32.6 million to $16.1 million for the first quarter of 2026, compared to $48.7 million for the same period in 2025.
- 3
General and administrative expenses were $10.1 million for the first quarter of 2026, a decrease of $0.4 million compared to $10.5 million for the same period in 2025.
- 4
Keros’ cash and cash equivalents as of March 31, 2026, was $281.5 million, compared to $287.4 million as of December 31, 2025.
- 5
The decrease in net loss was largely due to revenue recognized in 2025 related to Keros' license agreement with Takeda and decreased research and development efforts.
- 6
Keros expects that its cash and cash equivalents as of March 31, 2026 will enable it to fund its operating expenses and capital expenditure requirements into the first half of 2028.
Management Comments
Jasbir S. Seehra
Ph.D.
“Continuing to progress our pipeline remains our top priority, setting the stage for future catalysts and growth opportunities." “In addition, we are excited that our partner, Takeda Pharmaceuticals U.S.A., Inc. (“Takeda”), plans to advance elritercept into a Phase 3 clinical trial to evaluate elritercept as a treatment of anemia in myelofibrosis, broadening the indication opportunity beyond myelodysplastic syndromes.”
Informational and educational content only. Not investment advice.